Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study
Sibyl Wray, Eva Havrdová, David R. Snydman, et al.
Multiple Sclerosis Journal (2018) Vol. 25, Iss. 12, pp. 1605-1617
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
David Baker, Sandra Amor, Angray S. Kang, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 43, pp. 102174-102174
Open Access | Times Cited: 75
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
Nik Krajnc, Gabriel Bsteh, Thomas Berger, et al.
Neurotherapeutics (2022) Vol. 19, Iss. 3, pp. 753-773
Open Access | Times Cited: 45
Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis
Chi‐Yan Lee, Koon‐Ho Chan
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 120-120
Open Access | Times Cited: 15
Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
Catharina Korsukewitz, Stephen Reddel, Amit Bar‐Or, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 9, pp. 493-505
Open Access | Times Cited: 65
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Diego Centonze, Maria A. Rocca, Claudio Gasperini, et al.
Journal of Neurology (2021) Vol. 268, Iss. 11, pp. 3961-3968
Open Access | Times Cited: 52
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
Tjalf Ziemssen, Ann Bass, Regina Berkovich, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 973-988
Open Access | Times Cited: 50
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
Georges Jalkh, Rachelle Abi Nahed, Gabrielle Macaron, et al.
Vaccines (2020) Vol. 9, Iss. 1, pp. 12-12
Open Access | Times Cited: 42
Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
Stefanie Fischer, Undine Proschmann, Katja Akgün, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 3177-3177
Open Access | Times Cited: 33
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
Yahiya Y. Syed
Drugs (2020) Vol. 81, Iss. 1, pp. 157-168
Closed Access | Times Cited: 34
Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies
Jelena Drulović, Jovana Ivanović, Vanja Martinović, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 54, pp. 103150-103150
Open Access | Times Cited: 32
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
Irene Tramacere, Gianni Virgili, Vittorio Perduca, et al.
Cochrane library (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 11
Estudio abierto retrospectivo multicéntrico sobre la utilización de alemtuzumab en esclerosis múltiple remitente-recurrente en práctica clínica habitual. Seguimiento durante 4 años.
Antonio Pato Pato, Pablo Gabeiras Araujo, Marta E. García, et al.
Neurology Perspectives (2025), pp. 100192-100192
Open Access
Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma
Cecilia Larocca, Ai‐Tram N. Bui, John T. O’Malley, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
Federica Galota, Simone Marcheselli, Sara De Biasi, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 606-606
Open Access
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
Nora Möhn, Steffen Pfeuffer, Tobias Ruck, et al.
Neurology Neuroimmunology & Neuroinflammation (2019) Vol. 7, Iss. 2
Open Access | Times Cited: 31
Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis
Lucia Moiola, Paulus Rommer, Uwe K. Zettl
Current Opinion in Neurology (2020) Vol. 33, Iss. 3, pp. 286-294
Closed Access | Times Cited: 31
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years
Jiwon Oh, Anat Achiron, Elisabeth Gulowsen Celius, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 43, pp. 102146-102146
Open Access | Times Cited: 29
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
Jens Kühle, Nadia Daizadeh, Pascal Benkert, et al.
Multiple Sclerosis Journal (2021) Vol. 28, Iss. 4, pp. 573-582
Open Access | Times Cited: 25
Monoclonal Antibodies for Multiple Sclerosis: An Update
Jonas Graf, Orhan Aktaş, Konrad Rejdak, et al.
BioDrugs (2019) Vol. 33, Iss. 1, pp. 61-78
Closed Access | Times Cited: 27
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
Eva Fernández-Díaz, J. Gracia Gil, José Gregorio García-García, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 45, pp. 102402-102402
Open Access | Times Cited: 26
Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
Gilles Edan, Emmanuelle Le Page
Drugs (2023) Vol. 83, Iss. 15, pp. 1351-1363
Open Access | Times Cited: 9
Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs
Berenice Silva, Edgar Carnero Contentti, Jéfferson Becker, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 77, pp. 104840-104840
Closed Access | Times Cited: 8
Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center
Maria di Ioia, Vincenzo Di Stefano, D. Farina, et al.
Multiple Sclerosis and Related Disorders (2019) Vol. 38, pp. 101504-101504
Closed Access | Times Cited: 25
Disease-Modifying Therapies During the COVID-19 Outbreak
Smathorn Thakolwiboon, Hannah Zhao-Fleming, Jie Pan, et al.
International Journal of MS Care (2020) Vol. 22, Iss. 4, pp. 151-157
Open Access | Times Cited: 23
Immunology of COVID‐19 and disease‐modifying therapies: The good, the bad and the unknown
Tobias Zrzavy, Isabella Wimmer, Paulus Rommer, et al.
European Journal of Neurology (2020) Vol. 28, Iss. 10, pp. 3503-3516
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top